These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 32077767)

  • 1.
    Aminsharifi A; Silver D; Schulman A
    J Endourol; 2020 Feb; 34(2):242. PubMed ID: 32077767
    [No Abstract]   [Full Text] [Related]  

  • 2.
    Babayan RK; Steinberg ML; Miller LE
    J Endourol; 2020 Feb; 34(2):240-241. PubMed ID: 31914809
    [No Abstract]   [Full Text] [Related]  

  • 3. Major Complications and Adverse Events Related to the Injection of the SpaceOAR Hydrogel System Before Radiotherapy for Prostate Cancer: Review of the Manufacturer and User Facility Device Experience Database.
    Aminsharifi A; Kotamarti S; Silver D; Schulman A
    J Endourol; 2019 Oct; 33(10):868-871. PubMed ID: 31452385
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial Comment on: Device-Related Adverse Events During Percutaneous Nephrolithotomy: Review of the Manufacturer and User Facility Device Experience Database by Patel et al. (From: Patel NH, Schulman AA, Bloom JB, et al. J Endourol 2017;31:1007-1011).
    Andonian S
    J Endourol; 2018 Jan; 32(1):73-74. PubMed ID: 29084449
    [No Abstract]   [Full Text] [Related]  

  • 5. First experience in the Czech Republic with perirectal hydrogel injection before radiotherapy for prostate cancer.
    Vik V; Novotný T; Lukeš M; Holý P
    Klin Onkol; 2020; 33(6):440-444. PubMed ID: 33685193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter by Bilazarian et al. regarding the article, "Adverse events and modes of failure related to Impella RP: Insights from the Manufacturer and User Facility Device Experience (MAUDE) database" by Khalid et al.
    Bilazarian S; Bolt W
    Cardiovasc Revasc Med; 2019 Jul; 20(7):622. PubMed ID: 31088719
    [No Abstract]   [Full Text] [Related]  

  • 7. Late toxicities of prostate cancer radiotherapy with and without hydrogel SpaceAOR insertion.
    Te Velde BL; Westhuyzen J; Awad N; Wood M; Shakespeare TP
    J Med Imaging Radiat Oncol; 2019 Dec; 63(6):836-841. PubMed ID: 31520465
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Honey RJ
    J Endourol; 2019 Aug; 33(8):660. PubMed ID: 31056935
    [No Abstract]   [Full Text] [Related]  

  • 9. Improved rectal dosimetry with the use of SpaceOAR during high-dose-rate brachytherapy.
    Wu SY; Boreta L; Wu A; Cheung JP; Cunha JAM; Shinohara K; Chang AJ
    Brachytherapy; 2018; 17(2):259-264. PubMed ID: 29203149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes.
    Hwang ME; Mayeda M; Liz M; Goode-Marshall B; Gonzalez L; Elliston CD; Spina CS; Padilla OA; Wenske S; Deutsch I
    Radiat Oncol; 2019 Aug; 14(1):136. PubMed ID: 31375119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Placement of SpaceOAR hydrogel spacer for prostate cancer patients treated with iodine-125 low-dose-rate brachytherapy.
    Ghaffari H
    Int J Urol; 2020 May; 27(5):473. PubMed ID: 32141114
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Is a safety wire necessary during routine flexible ureteroscopy? (Citation: Dickstein RJ, Kreshover JE, Babayan RK, Wang DS. J Endourol 2010;24:1589-1592).
    Raynal G
    J Endourol; 2011 May; 25(5):881. PubMed ID: 21476835
    [No Abstract]   [Full Text] [Related]  

  • 13. Analysis of adverse events with Essure hysteroscopic sterilization reported to the Manufacturer and User Facility Device Experience database.
    Al-Safi ZA; Shavell VI; Hobson DT; Berman JM; Diamond MP
    J Minim Invasive Gynecol; 2013; 20(6):825-9. PubMed ID: 24183273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial Comment to Placement of SpaceOAR hydrogel spacer for prostate cancer patients treated with iodine-125 low-dose-rate brachytherapy.
    Tsumura H
    Int J Urol; 2020 Jan; 27(1):66. PubMed ID: 31680304
    [No Abstract]   [Full Text] [Related]  

  • 15. Device-Related Adverse Events During Percutaneous Nephrolithotomy: Review of the Manufacturer and User Facility Device Experience Database.
    Patel NH; Schulman AA; Bloom JB; Uppaluri N; Phillips JL; Konno S; Choudhury M; Eshghi M
    J Endourol; 2017 Oct; 31(10):1007-1011. PubMed ID: 28830243
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Lloyd GL; Chung ASJ; Steinberg S; Sawyer M; Williams DH; Overbey D
    J Endourol; 2019 Dec; 33(12):1045. PubMed ID: 31746654
    [No Abstract]   [Full Text] [Related]  

  • 17. Can a peri-rectal hydrogel spaceOAR programme for prostate cancer intensity-modulated radiotherapy be successfully implemented in a regional setting?
    Te Velde BL; Westhuyzen J; Awad N; Wood M; Shakespeare TP
    J Med Imaging Radiat Oncol; 2017 Aug; 61(4):528-533. PubMed ID: 28151584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel model to correlate hydrogel spacer placement, perirectal space creation, and rectum dosimetry in prostate stereotactic body radiotherapy.
    Hwang ME; Black PJ; Elliston CD; Wolthuis BA; Smith DR; Wu CC; Wenske S; Deutsch I
    Radiat Oncol; 2018 Oct; 13(1):192. PubMed ID: 30285812
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Gómez-Núñez JG
    J Endourol; 2019 Dec; 33(12):1043-1044. PubMed ID: 31565965
    [No Abstract]   [Full Text] [Related]  

  • 20. Feasibility of and rectal dosimetry improvement with the use of SpaceOAR® hydrogel for dose-escalated prostate cancer radiotherapy.
    van Gysen K; Kneebone A; Alfieri F; Guo L; Eade T
    J Med Imaging Radiat Oncol; 2014 Aug; 58(4):511-6. PubMed ID: 24580893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.